Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A Phase 1 Study of MVB-101 Administered Intraprostatically in Patients With Localized Prostate Cancer Who Are Scheduled for Radical Prostatectomy

13 novembre 2026 mis à jour par: MultiValent Biotherapies, Inc.

An Open-Label, Non-randomized, Multi-Center Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand Drug Conjugate MVB-101 Injected Into the Prostate of Patients With Localized Cancer of the Prostate Who Are Scheduled for Prostatectomy

This Phase 1, open-label, non-randomized, multicenter study will evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of MVB-101 administered by direct intraprostatic injection in adults with previously untreated localized adenocarcinoma of the prostate who are scheduled to undergo radical prostatectomy. Participants will receive MVB-101 once weekly for 4 weeks. Part A will use an i3+3 dose-escalation design to evaluate dose levels of 1, 2, 4, and 8 mg and determine the maximum tolerated dose and recommended Phase 2 dose. Part B will use a Simon two-stage dose-expansion design at one or more selected dose levels to further characterize safety and preliminary efficacy. Participants will undergo safety, pharmacokinetic, multiparametric magnetic resonance imaging, pathological, prostate-specific antigen, and patient-reported outcome assessments.

Aperçu de l'étude

Statut

Recrutement

Intervention / Traitement

Description détaillée

MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen (PSMA) and folate receptor alpha (FR-alpha) and carrying monomethyl auristatin E (MMAE). MVB-101 will be administered by direct injection into the prostate under transrectal ultrasound guidance, at a fixed total injection volume of 10 mL (5 mL per lobe), once per week for 4 weeks.

Part A will enroll up to 30 participants. Planned dose levels are 1, 2, 4, and 8 mg per dose. The dose-limiting toxicity evaluation period is Day 1 through Day 29. Accelerated titration rules will be applied to the first two dose levels, and an i3+3 design will guide dose selection. Higher, lower, or intermediate dose levels may be added based on emerging data and Safety Monitoring Committee recommendations. The recommended Phase 2 dose may be the same as or lower than the maximum tolerated dose.

Part B will enroll up to 29 participants per dose group at one or more selected dose levels and will use a Simon two-stage design to better estimate the recommended Phase 2 dose and further characterize safety and preliminary efficacy.

The study includes screening, treatment, safety follow-up approximately 28 days after the last dose, post-treatment multiparametric MRI and PSA assessment, and planned radical prostatectomy at approximately Day 90 (12 weeks). If radical prostatectomy is not performed, a post-treatment prostate biopsy will be obtained as close as possible to the planned prostatectomy date. End of study occurs after completion of safety follow-up, post-treatment MRI and PSA assessment, and prostatectomy or post-treatment biopsy.

Type d'étude

Interventionnel

Inscription (Estimé)

60

Phase

  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Alabama
      • Homewood, Alabama, États-Unis, 35209
        • Recrutement
        • Urology Centers of Alabama
        • Contact:
    • Texas

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Homme

La description

Inclusion Criteria:

  • Signed informed consent form.
  • Understands the obligation and is capable of attending all follow-up visits.
  • Documented, previously untreated, localized adenocarcinoma of the prostate confirmed by multiparametric MRI and prostate biopsy within 3 months before the first dose.
  • Scheduled for radical prostatectomy approximately 12 weeks after the first dose of MVB-101.
  • Gleason Grade Group 1 with at least one high-risk feature, or Grade Group 2, 3, or 4. High-risk features for Grade Group 1 are PSA density >0.2 ng/mL/cc, PI-RADS 4 or 5, lesion >1.0 cm, lesion volume >0.4 cc, or risk of extraprostatic extension evidenced by capsular abutment or bulge.
  • Prostate-specific antigen 20 ng/mL or less.
  • Eastern Cooperative Oncology Group performance status 0 or 1.
  • Adequate bone marrow and organ function.
  • Sexually active participants agree to use barrier protection during treatment and for 1 month after the last MVB-101 dose.

Exclusion Criteria:

  • Any prior treatment for prostate cancer, except prior active surveillance is permitted.
  • More than 10 mg/day of systemic steroids within 28 days before signing informed consent.
  • Prior exposure to auristatin, an auristatin derivative, or a similar molecule.
  • Prior or concurrent malignancy whose natural history or treatment could interfere with or affect MVB-101 safety or efficacy assessments.
  • Prostatic calcifications.
  • Inability to undergo MRI scanning for any reason, including claustrophobia or implanted devices.
  • Major surgery within 4 weeks before first dose or planned during the study, other than prostatectomy.
  • Toxicity attributed to prior anticancer therapy, other than alopecia and fatigue, not resolved to Grade 1 or baseline before first dose.
  • Poorly controlled concurrent disease, including diabetes or hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg).
  • Within 12 months before enrollment: cardiac angioplasty or stenting, myocardial infarction, unstable angina, coronary artery bypass graft surgery, symptomatic peripheral vascular disease, or NYHA class III or IV congestive heart failure.
  • History of clinically significant lung disease, including interstitial pneumonia, pneumonitis, pulmonary fibrosis, or severe radiation pneumonitis, or suspected disease on screening imaging.
  • Active bleeding disorder or other history of Grade 3 or higher hemorrhage within 4 weeks before first dose.
  • Need for oral vitamin K antagonist anticoagulant therapy. Low-dose anticoagulants to maintain central venous access patency or prevent deep venous thrombosis and therapeutic low-molecular-weight heparin are permitted.
  • Deep vein thrombosis or pulmonary embolism within 6 months before first dose.
  • Active infection requiring intravenous antibiotics within 1 week before first dose.
  • Uncontrolled HIV, known AIDS, chronic hepatitis B, occult hepatitis B, or hepatitis C.
  • Current or anticipated need for a strong CYP3A4 inhibitor or inducer. Prior use requires a washout of 21 days or 5 half-lives, whichever is longer, before first dose.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation séquentielle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Part A: MVB-101 1 mg

MVB-101 1 mg by intraprostatic injection once weekly for 4 weeks.

MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E.

Expérimental: Part A: MVB-101 2 mg

MVB-101 2 mg by intraprostatic injection once weekly for 4 weeks.

MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E.

Expérimental: Part A: MVB-101 4 mg

MVB-101 4 mg by intraprostatic injection once weekly for 4 weeks.

MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E.

Expérimental: Part A: MVB-101 8 mg

MVB-101 8 mg by intraprostatic injection once weekly for 4 weeks.

MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E.

Expérimental: Part B: MVB-101 Dose Expansion

MVB-101 at one or more selected dose levels by intraprostatic injection once weekly for 4 weeks. Other schedules may also be explored.

MVB-101 is a bi-ligand peptide-like drug conjugate targeting prostate-specific membrane antigen and folate receptor alpha and carrying monomethyl auristatin E.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Treatment-emergent adverse events
Délai: From first dose through safety follow-up (approximately Day 50); treatment-related adverse events are followed through end of study (approximately Day 90)

Number and percentage of participants with treatment-emergent adverse events, treatment-related adverse events, serious adverse events, and clinically significant changes in vital signs, physical examinations, electrocardiogram (ECG) and clinical laboratory tests, graded using NCI CTCAE version 6.0.

From first dose through safety follow-up (approximately Day 50); treatment-related adverse events are followed through end of study (approximately Day 90)
Dose-limiting toxicities
Délai: Day 1 through Day 29

Number and percentage of participants with a dose-limiting toxicity, assessed according to protocol-defined criteria using NCI CTCAE version 6.0.

Day 1 through Day 29
Maximum tolerated dose
Délai: Through completion of Part A dose escalation, up to 12 months

Maximum tolerated dose of intraprostatic MVB-101 determined from dose-limiting toxicities and cumulative safety data under the i3+3 design.

Through completion of Part A dose escalation, up to 12 months
Recommended Phase 2 dose
Délai: Through completion of dose escalation and applicable dose-expansion, up to 18 months

Recommended Phase 2 dose of intraprostatic MVB-101 based on safety, tolerability, pharmacokinetics, and available efficacy data.

Through completion of dose escalation and applicable dose-expansion, up to 18 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Pharmacokinetic parameters of MVB-101 and MMAE
Délai: Dose 1 and Dose 3: predose and 0.5, 2, 6, 24, 72, and 168 hours post-dose

Plasma concentration-time analysis will be performed using PK concentration values over time.

Dose 1 and Dose 3: predose and 0.5, 2, 6, 24, 72, and 168 hours post-dose
Pathological response in excised prostate tissue
Délai: At prostatectomy or post-treatment biopsy, approximately Day 90

Number and percentage of participants with persistence or absence of the dominant index prostate cancer lesion or any lesion on pathological examination of prostatectomy tissue; post-treatment multicore biopsy is used if planned prostatectomy is not performed.

At prostatectomy or post-treatment biopsy, approximately Day 90
Radiologic response by multiparametric MRI
Délai: Baseline and approximately 10 days, but no more than 14 days, before prostatectomy

Number and percentage of participants with persistence or absence of baseline prostate cancer lesions on post-treatment multiparametric MRI.

Baseline and approximately 10 days, but no more than 14 days, before prostatectomy
International Prostate Symptom Score
Délai: Baseline through safety follow-up (approximately Day 50)

Observed values and change from baseline in International Prostate Symptom Score (IPSS). IPSS score values between 0-5 with lower scores indicating better performance/ improvement.

Baseline through safety follow-up (approximately Day 50)
International Index of Erectile Function-5
Délai: Baseline through safety follow-up (approximately Day 50)

Observed values and change from baseline in International Index of Erectile Function-5 (IIEF-5). IIEF-5 is scored with values 1-5 with higher scores indicating better performance/ improvement.

Baseline through safety follow-up (approximately Day 50)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Directeur d'études: Stephen Snowdy, PhD, MultiValent Biotherapies, Inc.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

14 août 2026

Achèvement primaire (Estimé)

1 décembre 2027

Achèvement de l'étude (Estimé)

1 mars 2028

Dates d'inscription aux études

Première soumission

5 novembre 2026

Première soumission répondant aux critères de contrôle qualité

13 novembre 2026

Première publication (Réel)

18 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

13 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner